E-drug: MSF PRESS RELEASE - Pfizer South Africa Donation
-------------------------------------------------------------------------
PFIZER LIMITS SCOPE OF DONATION OF HIV DRUG IN SOUTH
AFRICA
- MSF Reiterates Demand that Pfizer Unconditionally Reduce Price or
Issue Voluntary License for Fluconazole -
Geneva (June 20, 2000) - The international medical aid agency
Medecins Sans Frontieres (MSF) today admonished Pfizer for not
making good on its promise to provide fluconazole (brand name
Diflucan) for free to people with HIV/AIDS in South Africa.
As negotiations proceed with the South African government on the
details of how the donation will be structured, the highly restrictive
nature of the offer is becoming clearer.
"The cumbersome conditions that Pfizer is imposing on its
much-publicized offer to provide fluconazole for free to people with
AIDS is disappointing," said Eric Goemaere, M.D., MSF, South Africa.
"Most outrageous is Pfizer's attempt to structure this donation like a
clinical trial, adding onerous reporting and training requirements. South
African physicians are experienced professionals and it is patronizing
to require special training for routine treatments. South African
physicians are currently diagnosing opportunistic infections that can
effectively be treated by fluconazole, but are unable to do so because
of the price."
In the ongoing negotiations between the South African government
and Pfizer, the company has placed other significant limitations and
restrictions on the proposed donation. Contrary to the initial demand,
the donation is being restricted to cryptococcal meningitis, which
means that oral thrush and life-threatening oesophageal candidiasis
will not be included. The company has also put a time limitation on
the offer.
If the South African government is not satisfied with Pfizer's proposal
to increase access to fluconazole, it could decide to issue a
compulsory license, granting the right of production or import to one
or more producers/suppliers. As Dr. Manto Tshabalala-Msimang, the
South African Minister of Health, explained at a World Health
Organization (WHO) conference this week, compulsory licensing is a
crucial tool to make HIV/AIDS drugs more widely available.
Generic fluconazole is currently sold for US$0.29 (daily dose for
cryptococcal meningitis) in Thailand. If Pfizer was to grant a voluntary
license to the South African government to import or manufacture
quality fluconazole the South Africans would be able to independently
meet the needs of AIDS patients who have both cryptococcal
meningitis and candidiasis.
Cryptococcal meningitis is a fungal infection of the brain that, if left
untreated, is fatal within two months. In South Africa the government
pays R29 (US$4.15) for a daily dose, a price which the government
can not afford to pay.
"South Africa is facing one of the world's most acute AIDS epidemics
with more than 10% of the population infected with HIV. More than
100,000 people died here of AIDS last year," said Dr. Goemaere. "It is
unacceptable that Pfizer still refuses to sell this product at an
affordable price in poor countries, or to let others have the legal right
to do so."
Sales of Diflucan were more than US$1 billion in 1999.
MSF continues to support TAC's initial request: Pfizer should reduce
the daily price of Diflucan in South Africa to below R4 (US$0.60) or
issue TAC a voluntary license to allow generic competition to reduce
prices to affordable levels. Pfizer has also rebuked similar requests
from other countries around the world.
Medecins Sans Frontieres (MSF) is conducting an international
campaign to improve access to essential medicines in poor countries.
For more information, see www.accessmed-msf.org.
For additional comment, contact:
Daniel Berman (Geneva): 41 79 286 9649
Toby Kasper (South Africa): 27 82 370 5307
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.